Valeant Completes Acquisition Of Natur Produkt In Russia

MONTREAL, Feb. 1, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of 
Natur Produkt International, JSC, a specialty pharmaceutical company in 
Russia, for approximately $163 million, plus adjustments for net debt and 
working capital.  Natur Produkt has a significant presence in the 
over-the-counter (OTC) segment in several categories marketed under the 
umbrella brand, Natur Produkt.  Key brands include AntiGrippin, a leading 
cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA brand names, 
leading sore throat remedies. 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of dermatology, 
neurology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Contact Information:  Laurie W. Little  949-461-6002  laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/01/c2385.html 
CO: Valeant Pharmaceuticals International, Inc.
NI: HEA MTC MNA  
-0- Feb/01/2013 13:50 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.